Dietary iodine intake, therapy with radioiodine, and anaplastic thyroid carcinoma

Clinical characteristic	Subgroup	All patients N = 220	Without history of RAI therapy N = 203	With history of RAI therapy N = 17	p-value
Gender	Male	68	66	2	0.10
Gender	Female	152	137	15	0.10
Age	70 years or less	124	114	10	1.00
Age	71 years or more	96	89	7	1.00
Year of diagnosis	1972–1986	95	89	6	0.023
	1987–2001	87	83	4
	2002–2017	38	31	7
Previous thyroid	No or no data	110	108	2	0.001
enlargement (> 1 year)	Yes	110	95	15	0.001
General condition	Good	92	85	7	0.063
	Moderate	58	57	1
	Poor	70	61	9
Tumor growth	≥ 3 months	173	157	16	0.13
Tumor growth	< 3 months	47	16	1	0.13
Local tumor extension	Extrathyroid	199	183	16	1.00
Local tumor extension	Intrathyroid	21	20	1	1.00
Tumor size	< 5 cm	35	34	1	0.50
	5–10 cm	105	96	9
	≥ 10 cm	80	73	7
Tumor volume (width² x length)/2	< 50 ml	16	16	0	0.19
	50–99 ml	37	36	1
	100–149 ml	22	20	2
	150–199 ml	18	18	0
	200 ml or more	127	113	14
Lymph nodes metastases	No	127	117	10	1.00
Lymph nodes metastases	Yes	93	86	7	1.00
Distant metastases	No	113	105	8	0.83
Distant metastases	Yes	107	98	9	0.83
Presentation of anaplastic carcinoma	Incidental	8	8	0	0.51
Presentation of anaplastic carcinoma	Evident	212	195	17	0.51
TNM stage	IVA	17	16	1	0.91
	IVB	96	89	7
	IVC	107	98	9
Thyroid surgery	Without surgery	130	117	13	0.56
	Biopsy	23	22	1
	Subtotal thyroidectomy	13	12	1
	Extracapsular lobectomy with isthmusectomy	17	17	0
	Total or near-total thyroidectomy	37	35	2
Residual tumor after surgery	Biopsy or no surgery	153	139	14	0.32
	R0	32	32	0
	R1	18	17	1
	R2	17	15	2
Lymph node dissection	No	211	194	17	1.00
Lymph node dissection	Yes	9	9	0	1.00
External beam irradiation	No	37	30	7	0.005
External beam irradiation	Yes	183	173	10	0.005
Dose of radiotherapy	Without or ≤ 20 Gy	54	47	7	0.244
	> 20 Gy and ≤ 45 Gy	74	70	4
	> 45 Gy	92	86	6
Chemotherapy	No	81	75	6	1.00
Chemotherapy	Yes	139	128	11	1.00
Death because of ATC	No (alive, other causes, lost from follow up)	13	12	1	1.00
Death because of ATC	Yes	207	191	16	1.00

Clinical characteristics of patients and 15-year periods

Clinical characteristic	Subgroup	All patients N = 220 Number	Patients 1972–1986 N=95 Number	Patients 1987–2001 N = 87 Number	Patients 2002-2017 N = 38 Number	p-value
Gender	Male	68	27	29	12	0.77
Gender	Female	152	68	58	26	0.77
Age	70 years or less	124	59	49	16	0.11
Age	71 years or more	96	36	38	22	0.11
History of radioiodine therapy	No	203	89	83	31	0.023
History of radioiodine therapy	Yes	17	6	4	7	0.023
Previous thyroid enlargement (> 1 year)	No or no data	110	46	49	26	0.036
Previous thyroid enlargement (> 1 year)	Yes	110	49	38	12	0.036
General condition	Good	92	47	33	12	0.13
	Moderate	58	25	20	13
	Poor	70	23	34	13
Tumor growth	≥ 3 months	173	70	72	31	0.29
Tumor growth	< 3 months	47	25	15	7	0.29
Local tumor extension	Extrathyroid	199	87	78	34	0.88
Local tumor extension	Intrathyroid	21	8	9	4	0.88
Tumor size	< 5 cm	35	20	12	3	0.043
	5–10 cm	105	40	39	26
	≥ 10 cm	80	35	36	9
Tumor volume (width² x length)/2	< 50 ml	16	7	5	4	0.68
	50–99 ml	37	19	14	4
	100–149 ml	22	6	12	4
	150–199 ml	18	9	7	2
	200 ml or more	127	54	49	24
Lymph nodes	No	127	45	54	28	0.012
metastases	Yes	93	50	33	10	0.012
Distant metastases	No	113	46	48	19	0.65
Distant metastases	Yes	107	49	39	19	0.65
Presentation of anaplastic carcinoma	Incidental	8	4	4	0	0.50
Presentation of anaplastic carcinoma	Evident	212	91	83	38	0.50
TNM stage	IVA	17	5	9	3	0.73
	IVB	96	41	39	16
	IVC	107	49	39	19
Thyroid surgery	Without surgery	130	48	52	30	0.029
	Biopsy	23	13	10	0
	Subtotal thyroidectomy	13	10	3	0
	Extracapsular lobectomy with isthmusectomy	17	9	7	1
	Total or near-total thyroidectomy	37	15	15	7
Residual tumor after surgery	Biopsy or no surgery	153	61	62	30	0.55
	R0	32	18	10	4
	R1	18	9	6	3
	R2	17	7	9	1
Lymph node dissection	No	211	90	83	38	0.36
Lymph node dissection	Yes	9	5	4	0	0.36
External beam irradiation	No	37	22	11	4	0.087
External beam irradiation	Yes	183	73	76	36	0.087
External beam irradiation	Without or ≤ 20 Gy	54	33	15	6	0.001
	> 20 Gy and 45 Gy	74	41	26	7
	> 45 Gy	92	21	46	25
Chemotherapy	No	81	38	24	19	0.04
Chemotherapy	Yes	139	57	63	19	0.04
Death because of anaplastic carcinoma	No (alive, other causes, lost from follow-up)	13	3	7	13	0.32
Death because of anaplastic carcinoma	Yes	207	92	80	25	0.32

eISSN:: 1581-3207
Język:: Angielski

Częstotliwość wydawania:: 4 razy w roku
Dziedziny czasopisma:: Medicine, Clinical Medicine, Internal Medicine, Haematology, Oncology, Radiology

Kanał RSS czasopisma

Dietary iodine intake, therapy with radioiodine, and anaplastic thyroid carcinoma

Article Category: Research Article

Data publikacji: 02 maj 2020

Zakres stron: 187 - 193

Otrzymano: 16 lis 2019

Przyjęty: 30 mar 2020

DOI: https://doi.org/10.2478/raon-2020-0023

© 2020 Nikola Besic, Barbara Gazic, published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Figure 1

Clinical characteristics of the patients and the history of radioiodine therapy

Clinical characteristics of patients and 15-year periods